<DOC>
	<DOCNO>NCT01455571</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) HM781-36B .</brief_summary>
	<brief_title>Phase I Study Determine Maximum Tolerated Dose Assess Safety Pharmacokinetic Profile HM781-36B Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Besides main objective , 3 objective follow : 1 . To determine dose-limiting toxicity ( DLT ) HM781-36B 2 . To characterize pharmacokinetics HM781-36B , follow oral administration HM781-36B 3 . To evaluate anticancer activity HM781-36B patient advance solid malignancy Groups 3 patient per cohort dose level treat escalating dos HM781-36B</detailed_description>
	<criteria>1 ) Histologically cytologically confirm advanced solid tumor 2 ) Patients experience progressive disease despite conventional anticancer therapy . Patients expect effective treatment prolong survival conventional anticancer therapy 3 ) Previous chemotherapy , radiotherapy surgical operation allow discontinue least 4 week prior D0 adverse event resolve 4 ) Aged ≥19 5 ) Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 6 ) A life expectancy great 12 week 7 ) Adequate bone marrow ( WBC≥4,000/mm3 platelet≥100000/mm3 , hemoglobin≥9.0g/dl ANC≥ 1500/mm3 , renal ( Creatinine≤1.5mg/dl ) liver function ( AST/ALT/ALP ≤ 3 x upper limit normal total bilirubin≤2mg/dl ) abnormal heart lung function However , AST/ALT/ALP ≤ 5 x upper limit normal patient liver metastasis ALP level ≤ 5 x upper limit normal patient bone metastases allow 8 ) Subjects must provide write informed consent prior performance study specific procedure assessment , must willing comply treatment follow assessment procedures 1 ) Patients hematopoietic malignancy , uncontrolled infection , ileus , CNS metastasis . 2 ) Patients undergone hematopoietic stem cell transplantation ( HSCT ) candidate plan HSCT 3 ) Class III IV heart failure ( NYHA Class ) LVEF &lt; 40 % 4 ) Patients GI malabsorption difficulty take oral medication 5 ) Patients psychiatric congenital disorder 6 ) Subjects , investigator 's opinion , treat per protocol due functional impairment 7 ) Pregnant breastfeed patient ; Women childbearing potential without adequate contraception ( Men must use adequate contraception . ) 8 ) Subjects intention follow requirement protocol followup management . Subjects follow regularly due psychological , social , family , logistic , geographical reason 9 ) Subjects administer investigational product within 30 day screen . 10 ) Subjects , investigator 's opinion , participate .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>